Related Experiment Video

Updated: May 21, 2026

Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells
09:25

Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells

Published on: August 19, 2016

Pathogenesis of group A streptococcal infections

Anna Henningham1, Timothy C Barnett, Peter G Maamary

  • 1School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, University of Queensland, St. Lucia, Queensland 4072, Australia.

Discovery Medicine
|May 31, 2012
PubMed

Insights

Group A Streptococcus (GAS) causes serious global health issues, from mild infections to life-threatening conditions. A GAS vaccine is crucial for future control due to antibiotic resistance concerns.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • Group A Streptococcus (GAS), or Streptococcus pyogenes, is a significant human pathogen responsible for global morbidity and mortality.
  • GAS infections range from common pharyngitis and impetigo to severe conditions like necrotizing fasciitis, streptococcal toxic shock syndrome (STSS), and bacteremia.
  • Repeated GAS infections can lead to severe non-suppurative sequelae, including acute rheumatic fever and acute glomerulonephritis.

Purpose of the Study:

  • To highlight the global health impact of Group A Streptococcus infections.
  • To discuss the limitations of current antibiotic treatments for GAS.
  • To emphasize the potential of a GAS vaccine for future disease control.

Main Methods:

  • This is a review and discussion of existing literature on GAS epidemiology, clinical manifestations, and treatment challenges.
  • Analysis of the current sensitivity of GAS to penicillin and concerns regarding emerging resistance.
  • Evaluation of the potential role of vaccination in preventing GAS infections.

Main Results:

  • GAS infections present a wide spectrum of disease severity and can lead to long-term complications.
  • Penicillin remains effective but faces challenges from patient compliance and potential antibiotic resistance.
  • Vaccination is proposed as a critical future strategy for controlling GAS.

Conclusions:

  • Group A Streptococcus poses a substantial global health burden, necessitating effective control strategies.
  • The emergence of antibiotic resistance and compliance issues underscore the need for alternative prevention methods.
  • A vaccine for GAS is essential for the future control and potential elimination of GAS-related diseases.

Related Concept Videos

Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Regulation of Bacterial Virulence01:28

Regulation of Bacterial Virulence

Pathogenic bacteria employ a range of regulatory mechanisms to modulate the expression of virulence genes in response to environmental and host-derived signals. These mechanisms ensure that virulence factors are expressed only under favorable conditions, thereby optimizing infection and survival strategies.Mechanisms of Virulence RegulationKey regulatory strategies include:Two-Component Systems: These consist of a membrane-bound sensor kinase and a cytoplasmic response regulator. Environmental...